Aston Martin Lagonda of Europe GmbH
Ergebnis der Suchanfrage nach Aggression
Inhalte
- Kategorie:
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- 10mehr
Aston Martin Lagonda of Europe GmbH
10INTRODUCING NEW VANTAGE: ENGINEERED FOR REAL DRIVERS
mehrRevenue Growth against a Backdrop of Massively Higher Energy and Raw Material Costs
mehrCOP28 and IEA Convene Global Energy Decision Makers to Accelerate a Just, Orderly Energy Transition
Goa, India (ots/PRNewswire) - - Series of dialogues will be held in partnership with IRENA and will be supported by the UNFCCC. - Dialogues aim to bring government and energy industry together to define how to accelerate action towards 1.5 degrees at COP28. - Session held on the sidelines of the 14th Clean Energy ...
mehrCOP28 President-Designate calls on oil & gas industry to allocate capital to clean energy solutions
Abu Dhabi, Uae (ots/PRNewswire) - - During the 8th OPEC International Seminar, held in Vienna, under the theme "Towards a Sustainable and Inclusive Energy Transition." Dr. Al Jaber thanked OPEC for playing an essential role in balancing energy markets, promoting global prosperity and advancing the goals of sustainable development. - "Dramatically reducing emissions, ...
mehrDEBIOPHARM LAUNCHES PHASE 1 RESEARCH IN SMALL CELL LUNG CANCER WITH WEE1 INHIBITOR DEBIO 0123 TO OUTSMART DDR IN SMALL CELL LUNG CANCER
Lausanne, Switzerland (ots) - - Debiopharm combines its potent WEE1-inhibitor Debio 0123 with standard-of-care therapy to short-circuit DNA damage repair (DDR) in adults with recurrent or progressive small cell lung cancer (SCLC). - The first patient dosed at Vall d’Hebron Hospital (Barcelona, Spain), was ...
mehrDEBIOPHARM LAUNCHES PHASE 1/2 COMBINATION TRIAL INVESTIGATING BRAIN-PENETRANT SELECTIVE WEE1 INHIBITOR FOR BRAIN CANCER PATIENTS
Lausanne (ots) - - Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%. - Debiopharm is combining its potent, brain penetrant WEE1 inhibitor Debio 0123 with standard of care (SOC) therapy. Debio 0123 hopes to hinder DNA damage ...
mehrDEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCi™ STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots/PRNewswire) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and ...
mehrDEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCiTM STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and treatment of ...
mehrYanis Varoufakis brutally attacked by a group of thugs in Athens
Ein DokumentmehrThe world's first Extended Isolated Stopflow Limb Infusion (EISLI) to treat osteosarcoma results in complete remission
mehr- 4
How AM is changing the manufacture and application of modern defence technology
Ein Dokumentmehr A majority of Europeans believe in a Ukraine victory
Gütersloh (ots) - One year after Russia began its war of aggression against Ukraine, 61 percent of Europeans are convinced Ukraine will prevail. But worries persist: 68 percent of respondents see the attack on Ukraine as an attack on all of Europe. One year into the war in Ukraine, 61% of Europeans believe that the country will prevail. Germans, however, are not quite so optimistic, although a 55% majority believes in a ...
mehrTechnische Universität München
Autonomous driving: New algorithm distributes risk fairly
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Software makes more ethically differentiated decisions Autonomous driving: New algorithm distributes risk fairly - Software doesn't just divide situations into either/or - Engineering and social sciences drive autonomous driving forward - Algorithm will also be tested on the road in the future Researchers at the Technical University of Munich (TUM) have developed autonomous ...
mehrArcwide Expands Global IFS Cloud Services Offering With Opening Of Chicago Office / Entry into North America forms part of "agressive growth plans"
Paris, France (ots) - Arcwide, the joint venture of BearingPoint and IFS dedicated to the deployment of IFS Cloud services, today announces the opening of an office in Chicago. The latest opening is Arcwide’s 12th in twelve different countries, a step towards its goal of 20 by 2025, and marks the company’s ...
mehrDEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY
Lausanne, Switzerland (ots) - Debiopharm awards the winning scientists for the JCA (Japanese Cancer Association) Award for innovative, disruptive, and translational oncology research Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, today announced the two winners of JCA Mauvernay ...
mehrIAPC Awards 2022 Democracy Medal to Ukrainian President Volodymyr Zelenskyy and The People of Ukraine
Washington, DC (ots) - --News Direct-- The International Association of Political Consultants (IAPC) announced today that it is awarding the prestigious 2022 Democracy Medal to the President of Ukraine, Volodymyr Zelenskyy on behalf of the Ukrainian people. The citation notes that this award is “in recognition of ...
mehrIs microplastic carcinogenic?
Graz/Vienna (ots) - The effects of micro- and nanoplastic particles (MNP) in the human body are being investigated in depth for the first time worldwide. From 2022 to 2025, research will be performed at CBmed together with international partners to elucidate potential health effects of microplastics. Every person in developed countries currently ingests an average of five grams of plastics per week - that's as much as a standard credit card. What these micro- and nanoplastic ...
mehrDeutsche Bundesstiftung Umwelt (DBU)
DBU: Just energy transition in the Global South
Ein DokumentmehrTechnische Universität München
Overcoming resistance of pancreatic cancer to immunotherapies
Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/37173 High resolution images: https://mediatum.ub.tum.de/1641984 NEWS RELEASE “Inflaming” cold tumors Overcoming resistance of pancreatic cancer to immunotherapies Pancreatic carcinoma is a ...
mehrTechnische Universität München
"Formula 1 could see driverless race cars as early as 2025"
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center Phone: +49 89 289 25439 – email: presse@tum.de – web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/37131 High resolution images: https://mediatum.ub.tum.de/1638696 NEWS RELEASE Interview with Prof. Markus Lienkamp on autonomous motor sports "Formula 1 could see driverless race cars as early as 2025" A team ...
mehr1NCE Appoints Ivo Rook as Chief Operating Officer
mehrBrenntag Polymers supports BLUE SAFETY in the development of an innovative bottle system for dental units
Ein DokumentmehrOpenSynergy Collaborates with Google and Qualcomm on Virtualizing Android Automotive OS
Berlin (ots) - OpenSynergy, today announced its yearlong collaboration with Google and Qualcomm on a reference platform with a virtualized Android Automotive OS instance running on top of OpenSynergy's COQOS Hypervisor SDK and Qualcomm's Snapdragon SA8155 automotive System on Chip (SoC). Google has announced collaborations with several vehicle manufacturers to power ...
mehrKat Florence drops 2019 collection due to shortage of D Flawless Diamonds
mehrSpectrum. The most dangerous artwork
The World's Most Dangerous Artwork / Cancer charity Deutsche Krebshilfe (German Cancer Aid), ADP, and the artistic duo LOW BROS welcomed guests to a somewhat unusual gallery opening
mehrHigh investor density at the Pitch Day hosted by IZB
Ein DokumentmehrTechnische Universität München
ERC Grants awarded to TUM researchers
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/detail/article/35313/ NEWS RELEASE Cutting-edge research from robotics to simulated flows ERC Advanced and Proof of Concept Grants awarded to TUM researchers The European Research Council (ERC) will fund three projects ...
mehrMundipharma EDO GmbH: US FDA Grants Orphan Drug Designation for Tinostamustine in Very Rare Blood Cancer
Basel, Switzerland (ots/PRNewswire) - FOR EX-US MEDICAL AND TRADE MEDIA ONLY - T-cell prolymphocytic leukaemia is an extremely rare and aggressive T-cell leukaemia, with very limited effective treatment options1,2 - Tinostamustine is in very early phase clinical trials to investigate it as a potential future ...
mehrTechnische Universität München
Toxic and aggressive, but widely used: Investigations with neutrons settle scientific dispute about the structure of fluorine
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/detail/article/35306/ High resulution images: https://mediatum.ub.tum.de/1482593 NEWS RELEASE Toxic and ...
mehr